A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis (SPIRIT-H2H)

I1F-MC-RHCF -

The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Psoriatic Arthritis
What the trial is testing?
Adalimumab, Ixekizumab
Could I receive a Placebo?
No
Enrollment Goal
566
Trial Dates
Aug 24, 2017 - Sep 4, 2019
How long will I be in the trial?
Your participation could last up to 15 months and include 12 visits to the study center.
Trial Phase
IV

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.